SID 26681509

CAS No. 958772-66-2

SID 26681509( —— )

Catalog No. M26442 CAS No. 958772-66-2

SID 26681509 is a selective, reversible and competitive human cathepsin L inhibitor (IC50 of 56 nM).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 132 Get Quote
10MG 205 Get Quote
25MG 413 Get Quote
50MG 618 Get Quote
100MG 881 Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    SID 26681509
  • Note
    Research use only, not for human use.
  • Brief Description
    SID 26681509 is a selective, reversible and competitive human cathepsin L inhibitor (IC50 of 56 nM).
  • Description
    SID 26681509 is a selective, reversible and competitive human cathepsin L inhibitor (IC50 of 56 nM).(In Vitro):After a 4 hr preincubation with cathepsin L, SID 26681509 becomes more potent(IC50 : 1.0 nM). SID 26681509 is determined to be a slow-binding and slowly reversible competitive inhibitor. Through a transient kinetic analysis for single-step reversibility, inhibition rate constants are kon = 24,000 M-1s-1 and koff = 2.2 × 10-5 s-1 (Ki = 0.89 nM). Molecular docking studies are undertaken using the experimentally-derived X-ray crystal structure of papain/CLIK-148. SID 26681509 inhibits papain and cathepsins B, K, S, and V with IC50 values determined after one hour ranging from 618 nM to 8.442 μM.(In Vivo):survival in murine models of sepsis significantly improved SID 26681509 by and reduces liver damage following warm liver ischemia/reperfusion (I/R) models.
  • In Vitro
    After a 4 hr preincubation with cathepsin L, SID 26681509 becomes more potent, demonstrating an IC50 of 1.0 nM. SID 26681509 is determined to be a slow-binding and slowly reversible competitive inhibitor. Through a transient kinetic analysis for single-step reversibility, inhibition rate constants are kon = 24,000 M-1s-1 and koff = 2.2 × 10-5 s-1 (Ki = 0.89 nM). Molecular docking studies are undertaken using the experimentally-derived X-ray crystal structure of papain/CLIK-148. SID 26681509 inhibits papain and cathepsins B, K, S, and V with IC50 values determined after one hour ranging from 618 nM to 8.442 μM. SID 26681509 shows no inhibitory activity against the serine protease cathepsin G. SID 26681509 inhibits cathepsin V activity with an IC50 value of 0.5 μM. SID 26681509 (1-30 μM) blocks high-mobility group box 1 (HMGB1)-induced TNF-α production dose dependently without altering cell viability.
  • In Vivo
    SID 26681509 treatment significantly improves survival in murine models of sepsis and reduces liver damage following warm liver ischemia/reperfusion (I/R) models.
  • Synonyms
    ——
  • Pathway
    Proteasome/Ubiquitin
  • Target
    Cysteine Protease
  • Recptor
    Hormone-sensitive lipase (HSL)
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    958772-66-2
  • Formula Weight
    539.65
  • Molecular Formula
    C27H33N5O5S
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 50 mg/mL (92.65 mM)
  • SMILES
    CCc1ccccc1NC(=O)CSC(=O)NNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)OC(C)(C)C
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Ebdrup, Soren, et al. PHARMACEUTICAL USE OF BORONIC ACIDS AND ESTERS THEREOF. US7037905.
molnova catalog
related products
  • VBY-825

    VBY-825 is a reversible inhibitor of cathepsin with high potency against cathepsins B, L, S and V.

  • JTE-607 HCl

    JTE-607 is a cytokine production inhibitor. JTE-607 induces apoptosis accompanied by an increase in p21waf1/cip1 in acute myelogenous leukemia cells.

  • Aurantiamide acetate

    Aurantiamide acetate was isolated from the fermentation broth of Aspergillus penicilloides for the first time. Aurantiamide acetate is a selective and orally active cathepsin inhibitor. Aurantiamide acetate has anti-inflammatory activities and can be used for the study of inflammatory diseases.